Quince Therapeutics(QNCX)
Focus: Quince Therapeutics is a public biotech company focused on neurological and inflammatory diseases, with a proprietary EryDex platform for red blood cell-based drug delivery. The company is early-stage with a pre-revenue profile and a pipeline centered on rare neurological indications.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Quince Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Quince Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Late-stage
5 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
International Ataxia Rating Scale in Younger Patients
Ataxia TelangiectasiaClinical Trials (1)
NCT01942850International Ataxia Rating Scale in Younger Patients
N/AHelp build intelligence for Quince Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.